NASDAQ:ATRAAtara Biotherapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Atara Biotherapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.17 -0.63 (-4.92 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's Range$11.92Now: $12.17▼$12.7150-Day Range$12.30MA: $13.63▼$15.5052-Week Range$4.52Now: $12.17▼$19.36Volume565,341 shsAverage Volume1.12 million shsMarket Capitalization$904.33 millionP/E RatioN/ADividend YieldN/ABeta2.23 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is developing ATA621 against the BK and JC viruses; ATA368 for patients with human papillomavirus and associated cancers; ATA520 to treat Wilms tumor 1; and ATA230 against cytomegalovirus and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 4.3 Analyst's Opinion Consensus RatingAtara Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 2.64, and is based on 8 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.11, Atara Biotherapeutics has a potential upside of 131.0% from its current price of $12.17.Amount of Analyst CoverageAtara Biotherapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.8 Community Rank Outperform VotesAtara Biotherapeutics has received 401 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAtara Biotherapeutics has received 318 “underperform” votes. (Add your “underperform” vote.)Community SentimentAtara Biotherapeutics has received 55.77% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Atara Biotherapeutics and other stocks. Vote “Outperform” if you believe ATRA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATRA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAtara Biotherapeutics does not currently pay a dividend.Dividend GrowthAtara Biotherapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atara Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $156,784.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Atara Biotherapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Atara Biotherapeutics are expected to grow in the coming year, from ($4.49) to ($4.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atara Biotherapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atara Biotherapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtara Biotherapeutics has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.55 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATRA Previous Symbol CUSIPN/A CIK1604464 Webwww.atarabio.com Phone650-278-8930Debt Debt-to-Equity Ratio0.04 Current Ratio11.33 Quick Ratio11.33Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.13 per share Price / Book2.37Profitability EPS (Most Recent Fiscal Year)($5.67) Net Income$-290,980,000.00 Net MarginsN/A Return on Equity-96.77% Return on Assets-83.82%Miscellaneous Employees321 Outstanding Shares74,308,000Market Cap$904.33 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $12.17 -0.63 (-4.92 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ATRA News and Ratings via Email Sign-up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions How has Atara Biotherapeutics' stock price been impacted by COVID-19? Atara Biotherapeutics' stock was trading at $9.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ATRA stock has increased by 22.2% and is now trading at $12.17. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Atara Biotherapeutics? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Atara Biotherapeutics. When is Atara Biotherapeutics' next earnings date? Atara Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Atara Biotherapeutics. How were Atara Biotherapeutics' earnings last quarter? Atara Biotherapeutics Inc (NASDAQ:ATRA) released its earnings results on Wednesday, August, 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.21) by $0.07. View Atara Biotherapeutics' earnings history. What price target have analysts set for ATRA? 11 analysts have issued 12 month target prices for Atara Biotherapeutics' stock. Their forecasts range from $9.00 to $70.00. On average, they expect Atara Biotherapeutics' share price to reach $28.11 in the next year. This suggests a possible upside of 131.0% from the stock's current price. View analysts' price targets for Atara Biotherapeutics. Has Atara Biotherapeutics been receiving favorable news coverage? Media stories about ATRA stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Atara Biotherapeutics earned a coverage optimism score of 0.6 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Atara Biotherapeutics. Are investors shorting Atara Biotherapeutics? Atara Biotherapeutics saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 11,980,000 shares, an increase of 17.1% from the April 15th total of 10,230,000 shares. Based on an average daily trading volume, of 855,700 shares, the short-interest ratio is presently 14.0 days. Currently, 22.8% of the company's stock are sold short. View Atara Biotherapeutics' Short Interest. Who are some of Atara Biotherapeutics' key competitors? Some companies that are related to Atara Biotherapeutics include Relay Therapeutics (RLAY), Sorrento Therapeutics (SRNE), Momenta Pharmaceuticals (MNTA), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Twist Bioscience (TWST), Immunovant (IMVT), Legend Biotech (PCVX), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Mesoblast (MESO), Sangamo Therapeutics (SGMO), BAVARIAN NORDIC/S (BVNRY), Revolution Medicines (RVMD) and Coherus Biosciences (CHRS). View all competitors. What other stocks do shareholders of Atara Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include Crispr Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Gilead Sciences (GILD), Micron Technology (MU), Pfizer (PFE), Sorrento Therapeutics (SRNE) and Amarin (AMRN). Who are Atara Biotherapeutics' key executives? Atara Biotherapeutics' management team includes the following people: Dr. Isaac E. Ciechanover, Pres, CEO & Director (Age 48)Mr. Utpal Koppikar, Chief Financial Officer (Age 49)Mr. Joseph Newell, Exec. VP & Chief Technical Operations Officer (Age 49)Ms. Mina Kim, Sr. VP of Corp. Strategy, Gen. Counsel & Sec. (Age 45)Dr. Dietmar P. Berger M.D., Ph.D., Global Head of R&D (Age 56) What is Atara Biotherapeutics' stock symbol? Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA." Who are Atara Biotherapeutics' major shareholders? Atara Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.25%), Goldman Sachs Group Inc. (4.75%), FMR LLC (2.71%), Canada Pension Plan Investment Board (1.96%), Assenagon Asset Management S.A. (1.31%) and Marshall Wace LLP (1.04%). Company insiders that own Atara Biotherapeutics stock include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Eric Dobmeier, Isaac E Ciechanover, Joe Newell, Joel S Marcus, Pascal Touchon and Utpal Koppikar. View institutional ownership trends for Atara Biotherapeutics. Which major investors are selling Atara Biotherapeutics stock? ATRA stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Canada Pension Plan Investment Board, Bank of America Corp DE, UBS Group AG, and Trexquant Investment LP. Company insiders that have sold Atara Biotherapeutics company stock in the last year include Joe Newell, Pascal Touchon, and Utpal Koppikar. View insider buying and selling activity for Atara Biotherapeutics. Which major investors are buying Atara Biotherapeutics stock? ATRA stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., FMR LLC, Vanguard Group Inc., Assenagon Asset Management S.A., Marshall Wace LLP, Wasatch Advisors Inc., Alyeska Investment Group L.P., and Alberta Investment Management Corp. View insider buying and selling activity for Atara Biotherapeutics. How do I buy shares of Atara Biotherapeutics? Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Atara Biotherapeutics' stock price today? One share of ATRA stock can currently be purchased for approximately $12.17. How big of a company is Atara Biotherapeutics? Atara Biotherapeutics has a market capitalization of $904.33 million. The biotechnology company earns $-290,980,000.00 in net income (profit) each year or ($5.67) on an earnings per share basis. Atara Biotherapeutics employs 321 workers across the globe. What is Atara Biotherapeutics' official website? The official website for Atara Biotherapeutics is www.atarabio.com. How can I contact Atara Biotherapeutics? Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930. This page was last updated on 8/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
